About this trial
A prospective, multicenter, open-label, blinded-endpoint, randomized controlled trial to evaluate whether best medical management (BMM) combined with endovascular therapy (EVT) improves neurological outcomes compared to BMM alone in patients with progressive acute mild ischemic stroke due to basilar artery occlusion within an extended time window.
Eligibility criteria
Qualifiers
Age ≥18 years.
Symptoms and signs consistent with basilar artery ischemia.
Basilar artery or vertebral artery occlusion confirmed by computed tomography angiography (CTA), magnetic resonance angiography (MRA), or digital subtraction angiography (DSA); if vertebral artery occlusion is present, it should completely block blood flow along the basilar artery.
First-time onset meeting the criteria for mild ischemic stroke diagnosis: NIHSS score <6.
Disqualifiers
Symptom progression due to intracranial hemorrhage, brain edema, or other clear causes (including but not limited to infarct hemorrhagic transformation, new infarction in non-occluded vascular regions, severe infection, high fever, heart or kidney dysfunction, hypovolemia, or severe electrolyte disturbances).
mRS >2.
Factors in the target vessel that are expected to prevent completion of endovascular treatment.
Multiple vessel occlusions.
Trial design
Treatments tested in this trial
- Endovascular Treatment